🔗 Share this article

While America proceeds with unprecedented revisions to its immunization schedules, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who initially gained attention by questioning COVID-19 vaccines during the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Immunization Program

Health officials had intended to reveal major revisions to the childhood vaccine schedule in December, bringing the US with the Danish national calendar, it is understood – a major change that would put the US out of step with a large portion of the global community with little proof for benefit. The announcement has been postponed until the new year.

In place of the director of the vaccine center, Høeg is listed to speak at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

A New Direction at the Agency

This interim role may indicate a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific childhood vaccine recommendations in the US to become more in line with Denmark, a nation with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on vaccines – traditionally the purview of Prasad, head of the FDA’s CBER – as opposed to medication approval.

Concerns Over Background

Høeg has little discernible background in medication creation, regulation or leadership, which has been standard for past leaders of the biologics center. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She appears not to have the necessary background” for running the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “grasp laws and regulations and the science of drug development”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who headed the center have had.”

CDER has an immense portfolio at the FDA, Woodcock pointed out.

“The public just zeroes in on the innovative therapies, but the generic program approves thousands of generic drugs. There’s a biosimilars program, OTC medication office and other areas, and all of those must be supervised,” she said. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major administrative element to the role, which oversees more than 5,000 personnel. “It’s a enormous management job, if you perform it correctly,” Woodcock added.

Agency Reaction and Disputed Initiatives

Regarding questions about Dr. Høeg's qualifications and whether this selection indicates more teamwork among agency officials on immunizations, a press secretary stated that the “concerns are based on inaccurate premises”.

“Her resume matches the functions of her job,” the official said, pointing to the time Dr. Høeg spent advising the agency head on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the agency head's controversial priority voucher program, a disputed rapid medication authorization process that reportedly worried her former heads. “By what process are these medications being chosen for this voucher program? Who is making the choices?” Dr. Howard said. “There is a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the agency seems to be moving towards more relaxed rules of most medications, aside from immunizations.”

Public Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, track record, critics have noted. She released a study using unverified volunteer-provided data to assess the rate of heart inflammation following COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming administration included changing regulations for novel immunizations and discontinuing “optional” vaccines, she said following the vote on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of preventing young men from getting Covid vaccines.

“She is an all-around true believer who starts off with her preconceived notions and works backwards to accommodate the data in a extremely misleading, untruthful fashion,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg aligned with other contrarians, {like|